Journal of the American Chemical Society · 2014 · 127 citations · 29 references
PharmacyMedicinal ChemistryPharmaceuticsDrug DeliveryMolecular PharmacologyMucosal Drug DeliveryCell-penetrating Delivery SystemsCell-penetrating PeptidesDrug EncapsulationNucleic Acid DeliveryPeptide DeliveryTargeting LigandsFunctionalizationNucleic Acid TherapeuticsPeptide ConjugatesPeptide Delivery SystemsPeptide-drug ConjugatesPeptide-mediated DeliverySelectivityTargeted Transfection
The use of stimuli-responsive bioactive molecules is an attractive strategy to circumvent selectivity issues in vivo. Here, we report an activatable cell penetrating peptide (CPP) strategy ultimately aimed at delivering nucleic acid drugs to the colon mucosa using bacterial azoreductase as the local reconversion trigger. Through screening of a panel of CPPs, we identified a sequence (M918) capable of carrying a nucleic acid analogue payload. A modified M918 peptide conjugated to a peptide nucleic acid (PNA) was shown to silence luciferase in colon adenocarcinoma cells (HT-29-luc). Reversible functionalization of the conjugate's lysine residues via an azobenzene self-immolative linkage abolished transfection activity, and the free CPP-PNA was recovered after reduction of the azobenzene bond. This activatable CPP conjugate platform could find applications in the selective delivery of nucleic acid drugs to the colon mucosa, opening therapeutic avenues in colon diseases.
29
Transvascular delivery of small interfering RNA to the central nervous system
Priti Kumar, Haoquan Wu, Jodi L. McBride et al. · Nature · 2007 · 1.2K citations